van Bommel P F, Kenemans P, Helmerhorst T J, Gallee M P, Ivanyi D
Department of Obstetrics and Gynecology, Ignatius Hospital, Breda, The Netherlands.
Cancer. 1994 Oct 15;74(8):2314-20. doi: 10.1002/1097-0142(19941015)74:8<2314::aid-cncr2820740816>3.0.co;2-1.
The identification of pretreatment markers with predictive significance for the presence of lymph node metastases and treatment outcome in low stage cancer of the uterine cervix is clinically important. Because the presence of differentiation-related markers varies in this type of cancer, the authors investigated whether loss of these markers is related to a poor clinical course.
An indirect immunoperoxidase technique was applied to formalin fixed, paraffin embedded tissue sections of 80 patients with International Federation of Gynecology and Obstetrics Stage IB and IIA primary squamous cell cervical carcinomas for detection of expression of cytokeratin 10 and 13, and involucrin. Comparisons were made of the expression of each of these markers among 40 patients with regional node metastases and 40 age-matched patients with no lymph node metastases. Differences in the frequency of expression of these markers also were analyzed in relation to histopathologic characteristics, recurrence, and survival.
Expression of cytokeratin 10, 13, and involucrin was found in 24, 64, and 53%, respectively, of all patients studied. The authors found no differences between patients with positive regional lymph nodes and those with negative lymph nodes. Expression of cytokeratin 13 and involucrin was associated with tumor grade (P = 0.01). No relationship was found between expression of the markers used and recurrence or survival in the entire group. Within the lymph node-positive group, however, the survival rate of patients with tumors with cytokeratin 13 expression was significantly higher than that of patients with tumors lacking cytokeratin 13 expression (P = 0.02).
Expression of cytokeratin 10, 13, or involucrin in the primary tumor is of no predictive value with respect to the presence of regional lymph node metastases in low stage squamous cell cervical cancer. However, cytokeratin 13 expression appears to be of prognostic significance in patients with positive regional lymph nodes.
识别对子宫颈低分期癌患者淋巴结转移情况及治疗结果具有预测意义的预处理标志物具有重要的临床意义。由于这类癌症中分化相关标志物的存在情况各异,因此作者研究了这些标志物的缺失是否与不良临床病程相关。
采用间接免疫过氧化物酶技术,对80例国际妇产科联盟(FIGO)分期为IB和IIA期的原发性宫颈鳞状细胞癌患者经福尔马林固定、石蜡包埋的组织切片进行检测,以检测细胞角蛋白10、13和内披蛋白的表达。对40例有区域淋巴结转移的患者和40例年龄匹配无淋巴结转移的患者的上述各标志物表达情况进行比较。还分析了这些标志物表达频率与组织病理学特征、复发及生存情况的差异。
在所研究的所有患者中,细胞角蛋白10、13和内披蛋白的表达率分别为24%、64%和53%。作者发现区域淋巴结阳性患者与阴性患者之间无差异。细胞角蛋白13和内披蛋白的表达与肿瘤分级相关(P = 0.01)。在所研究的整个组中,未发现所使用的标志物表达与复发或生存之间存在关联。然而,在淋巴结阳性组中,细胞角蛋白13表达阳性的肿瘤患者的生存率显著高于缺乏细胞角蛋白13表达的肿瘤患者(P = 0.02)。
原发性肿瘤中细胞角蛋白10、13或内披蛋白的表达对于低分期宫颈鳞状细胞癌区域淋巴结转移的存在无预测价值。然而,细胞角蛋白13表达似乎对区域淋巴结阳性患者具有预后意义。